AKBA
What one share of Akebia Therapeutics holds
Pharmaceutical Preparations
We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease.
Akebia Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.83 |
|---|---|
| Profit | −$0.11 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.15 |
| Cash and investments | $0.57 |
| Debt | $0.18 |
| Book value | $0.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$3.60 | $0.07 | $1.46 | — | $1.76 |
| 2017 | $4.17 | −$1.69 | $0.04 | −$1.33 | — | $2.57 |
| 2018 | $3.58 | −$2.47 | $0.03 | −$1.71 | — | — |
| 2019 | $2.83 | −$2.36 | $0.06 | −$2.23 | — | $3.23 |
| 2020 | $2.13 | −$2.78 | $0.00 | −$0.80 | — | $1.65 |
| 2021 | $1.28 | −$1.70 | $0.00 | −$1.52 | — | $0.42 |
| 2022 | $1.60 | −$0.52 | $0.00 | −$0.40 | — | $0.03 |
| 2023 | $1.04 | −$0.28 | $0.00 | −$0.12 | — | −$0.16 |
| 2024 | $0.76 | −$0.33 | $0.00 | −$0.19 | — | −$0.22 |
| 2025 | $0.92 | −$0.02 | $0.00 | $0.26 | — | $0.12 |